Nomura Floating Rate Fund Outperforms Benchmark in Q2 2026 Amidst Economic Headwinds
Finance

Nomura Floating Rate Fund Outperforms Benchmark in Q2 2026 Amidst Economic Headwinds

authorBy Mariana Mazzucato
DateJul 12, 2026
Read time3 min

In the second quarter of 2026, the Nomura Floating Rate Fund's Institutional Class shares delivered an impressive performance, exceeding its established benchmark, the Morningstar LSTA US Leveraged Loan Index. This noteworthy achievement took place amidst a complex economic landscape, which saw significant loan primary activity, indicating a resilient market despite prevailing macroeconomic challenges. The fund's strategic positioning and active risk management enabled it to navigate through a period marked by persistent inflation, geopolitical uncertainties, and the ongoing specter of interest rate adjustments, alongside emerging concerns regarding the impact of artificial intelligence across various industries.

During the second fiscal quarter of 2026, the Morningstar LSTA US Leveraged Loan Index recorded a positive return of 1.88%. This reflected widespread positive performance across all loan rating categories, a notable recovery following a volatile preceding quarter and in the context of a demanding market environment. Loans rated B demonstrated a particularly strong showing, leading the gains with a return of 1.97%. The total volume of primary loan activity reached $224 billion, which, although a 7% decrease from the first quarter, still indicated a remarkable resilience that defied broader macroeconomic anxieties.

The financial markets observed during this period were characterized by a cautious optimism, with investors closely monitoring inflation trends and central bank policies. Geopolitical developments added another layer of complexity, influencing market sentiment and investment flows. Amidst these factors, the leveraged loan market showed robustness, suggesting underlying strength in corporate fundamentals for many issuers. However, the emergence of AI as a potential disruptor introduced new considerations for credit analysis, prompting a re-evaluation of risks across different sectors.

Looking ahead, the outlook for the leveraged loan market remains dynamic. Expectations for default rates are anticipated to be within the 2.0% to 3.0% range, necessitating a continuous emphasis on astute credit selection. The portfolio's composition is being carefully managed to enhance its ability to withstand potential economic shocks and capitalize on opportunities arising from sector-specific dynamics. The strategic focus is on identifying companies with strong balance sheets and sustainable business models, capable of navigating the evolving economic and technological landscape. This proactive approach aims to ensure the fund's continued resilience and ability to deliver value for investors.

The impressive performance of the Nomura Floating Rate Fund in the second quarter of 2026 underscores the effectiveness of its investment strategy in a complex global market. By skillfully managing exposure to various sectors and maintaining a rigorous selection process, the fund was able to capitalize on opportunities while mitigating risks. The focus on strong credit fundamentals, coupled with a keen awareness of macroeconomic shifts and technological advancements like AI, positions the fund to continue its robust performance trajectory.

More Articles
Finance
AI's Impact on Q2 Earnings: A New Era of Optimism
Silicon Valley's shift towards prioritizing AI investments over share buybacks signals a new era for US equities. The focus for upcoming earnings will likely be on companies' AI efficiency roadmaps and future deployment strategies, rather than immediate returns on investment. Energy and computational constraints currently limit widespread AI adoption, making qualitative progress and cost-reduction plans key drivers of near-term market sentiment. This indicates a secularly bullish outlook for US equities, as the market increasingly values forward-looking AI strategies.
By Lisa JingJul 12, 2026
Finance
Micron: The Illusion of a Low P/E Ratio Amidst Market Volatility
Micron's stock has seen a remarkable surge, with its valuation reaching an astounding $1.1 trillion. This surge is primarily fueled by a temporary imbalance in the global supply chains of DRAM and NAND. The company is projected to hit peak earnings by fiscal year 2028, with an estimated $163.85 per share. Recent financial reports for Q3-26 indicate a 67% quarter-over-quarter increase in Micron's DRAM revenues, largely due to a significant rise in average selling prices, while shipment volumes remained relatively stable. The company has ambitious investment plans, committing over $250 billion to the United States by 2035.
By Mariana MazzucatoJul 12, 2026
Finance
STMicroelectronics: Overvalued, Downgraded to 'HOLD'
STMicroelectronics has experienced a remarkable 190% return on investment, primarily fueled by a surge in AI demand and its initial undervaluation. However, its current valuation, with a trailing P/E ratio exceeding 400x and a forward P/E above 40x, significantly surpasses both its fundamental performance and peer averages. This has prompted a downgrade to 'HOLD' due to concerns over its high valuation, weakening margin normalization, and increased risks associated with its exposure to the automotive and industrial sectors.
By Michele FerreroJul 12, 2026
Finance
Assessing Meta Platforms as a Long-Term Investment
This article explores whether Meta Platforms is a viable long-term investment by analyzing its financial health, AI investments, and market performance. It delves into Meta's capital allocation, profitability, and AI monetization strategies, encouraging investors to look beyond daily stock fluctuations. The piece also examines past spending on the metaverse versus current AI initiatives and provides an analyst's rating, offering a comprehensive view for potential long-term investors.
By Strive MasiyiwaJul 12, 2026
Finance
BridgeBio Pharma: A Strong Buy for Biotech Innovation and Market Expansion
BridgeBio Pharma continues to be a top recommendation, driven by successful regulatory approvals, a robust development pipeline, and strong commercial performance of its key therapeutic, Attruby. The company is advancing multiple New Drug Applications and securing its financial future with strategic funding to support ongoing research and market penetration.
By Fareed ZakariaJul 12, 2026